Advertisement

Site search sponsored by Micromeritics

Purifying DNA from buccal swabs

DNA Research Innovation

General company product range

In comparison to invasive techniques used for sourcing DNA such as the taking of blood samples, the buccal swabs procedure is quick and painless and can be carried out by non-trained users

DNA Research Innovation (DRI), a supplier of products for manualand automated nucleic acid extraction, has announced the signingof a new OEM distribution agreement with buccal swab innovatorIsohelix.

DRI will non-exclusively supply for re-sale itsChargeSwitch genomic DNA purification kits for buccal cells toIsohelix for manual and automated use.

Buccal swabs are widelyused to non-invasively remove cheek lining cells from individualswhich are then processed to extract DNA.

This methodology isroutinely used worldwide for criminal justice DNA databasing,clinical genotyping and lifestyle genotyping.

In comparison toinvasive techniques used for sourcing DNA such as the taking ofblood samples, the buccal swabs procedure is quick and painlessand can be carried out by non-trained users.

Due to the rapidexpansion of clinical and lifestyle genotyping and the wider useof national criminal databases, there is a growing need forrapid, high yield and effective methods for DNA extraction frombuccal swabs to replace blood based protocols.

DRI markets rapidDNA and RNA purification kits based on its patented ChargeSwitchtechnology.

ChargeSwitch protocols do not require the use of PCRinhibitors such as alcohols, concentrated chaotropic salts ororganic solvents and has received leading endorsements in theapplication of DNA extraction from buccal swabs.

Isohelix marketsthe T-Swab buccal swab and Autohelix methodology for high yieldand high throughput swab processing.

This new relationship isaimed to further enable Isohelix to penetrate existing and novelUS and European markets.

"This agreement gives us additionalexposure and methods of distribution into the forensic andclinical genotyping community," said Simon Douglas, CEO ofDRI.

"The combination of the high yield T-Swab andinnovative ChargeSwitch technology will greatly enhancethroughput and yield for major laboratories.

"Thisrelationship is very much in line with our OEM strategy and welook forward to seeing an expansion of our existing customerbase".

"Within the nucleic acid purification market,DRI's technology is very unique and very effective,"added Ernest Poku, CEO of Isohelix.

"The high DNA yield andsimplicity of protocols for both manual and automated extractionmade DRI a strong partner of choice for us.

This agreement willbe beneficial to both parties."

Add to my alerts

You need to be logged in to add alerts.

Sign in

Separation Techniques Special

alt text